SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
2.460
0.00 (0.00%)
Nov 20, 2025, 11:18 AM EST - Market open
SciSparc Employees
SciSparc had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
$463,500
Profits / Employee
-$6,085,000
Market Cap
3.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Dec 31, 2021 | 3 | 1 | 50.00% |
| Dec 31, 2020 | 2 | -6 | -75.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRC News
- 4 hours ago - SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - GlobeNewsWire
- 1 day ago - Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - TheNewswire
- 27 days ago - SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio - GlobeNewsWire
- 27 days ago - SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 weeks ago - SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery - GlobeNewsWire
- 4 weeks ago - Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc. - TheNewswire
- 4 weeks ago - SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders - GlobeNewsWire
- 5 weeks ago - SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio - GlobeNewsWire